EPA, FDA Agreements Aim To Clear Up Burdensome Regulatory Environment
This article was originally published in The Gray Sheet
Executive SummaryComplex, overlapping federal regulations potentially are blocking availability of innovative disinfectants for medical uses, speakers at a recent Food & Drug Law Institute meeting suggested
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.